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Abstract
Background: In guinea pigs, we have previously demonstrated that the contribution of Rho-kinase
to airway responsiveness in vivo and ex vivo is enhanced after active sensitization with ovalbumin
(OA). Using conscious, unrestrained OA-sensitized guina pigs, we now investigated the role of
Rho-kinase in the development of airway hyperresponsiveness (AHR) after the allergen-induced
early (EAR) and late asthmatic reaction (LAR) in vivo.
Methods: Histamine and PGF2α PC100-values (provocation concentrations causing 100% increase
in pleural pressure) were assessed before OA-challenge (basal airway responsiveness) and after the
OA-induced EAR (5 h after challenge) and LAR (23 h after challenge). Thirty minutes later, saline
or the specific Rho-kinase inhibitor Y-27632 (5 mM, nebulizer concentration) were nebulized, after
which PC100-values were reassessed.
Results: In contrast to saline, Y-27632 inhalation significantly decreased the basal responsiveness
toward histamine and PGF2α before OA-challenge, as indicated by increased PC100 -values. Both
after the allergen-induced EAR and LAR, AHR to histamine and PGF2α was present, which was
reversed by Y-27632 inhalation. Moreover, there was an increased effectiveness of Y-27632 to
reduce airway responsiveness to histamine and PGF2α after the EAR and LAR as compared to pre-
challenge conditions. Saline inhalations did not affect histamine or PGF2α PC100-values at all.
Interestingly, under all conditions Y-27632 was significantly more effective in reducing airway
responsiveness to PGF2α as compared to histamine. Also, there was a clear tendency (P = 0.08) to
a more pronounced degree of AHR after the EAR for PGF2α than for histamine.
Conclusion: The results indicate that inhalation of the Rho-kinase inhibitor Y-27632 causes a
considerable bronchoprotection to both histamine and PGF2α. Moreover, the results are indicative
of a differential involvement of Rho-kinase in the agonist-induced airway obstruction in vivo.
Increased Rho-kinase activity contributes to the allergen-induced AHR to histamine and PGF2α
after both the EAR and the LAR, which is effectively reversed by inhalation of Y-27632. Therefore,
Rho-kinase can be considered as a potential pharmacotherapeutical target in allergic asthma.
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Background
Asthma is an inflammatory airways disease characterized
by airway hyperresponsiveness (AHR) to a variety of stim-
uli, including contractile agonists such as histamine and
prostaglandin F2α (PGF2α) [1-4].
Agonist-induced smooth muscle contraction is largely
governed by phosphorylation of the 20kDa myosin light
chain (MLC20) [5]. MLC20 phosphorylation is initiated by
an increase in intracellular Ca2+-concentration ([Ca2+]i)
and subsequent formation of Ca2+-calmodulin, resulting
in activation of myosin light chain kinase (MLCK). The
extent of MLC20 phosphorylation is determined by the
balance between MLCK and myosin light chain phos-
phatase (MLCP) activities [6]. Recently, it has been estab-
lished that contractile stimuli do not exert their effects
only by increasing [Ca2+]i, but also by increasing the sen-
sitivity of the contractile apparatus to Ca2+. One of the
main pathways involved in this Ca2+-sensitization is the
RhoA/Rho-kinase pathway [7,6]. Activated Rho-kinase
interferes with the equilibrium of MLCK and MLCP activ-
ities by phosphorylating and thereby inactivating the
myosin binding subunit of MLCP. This leads to an aug-
mentation of MLC20 phosphorylation and hence an ele-
vated level of contraction at an established [Ca2+]i [7,8].
In vitro studies have indicated a receptor-dependent role
of Rho-kinase in agonist-induced airway smooth muscle
(ASM) contraction. Thus, the potency and maximal effect
of histamine-induced contraction of guinea pig tracheal
smooth muscle preparations were unaffected by inhibi-
tion of Rho-kinase, whereas these parameters were
strongly dependent on Rho-kinase for PGF2α-induced
contraction [9]. Growth factor-induced contraction of
human and guinea pig ASM preparations appeared to be
almost completely dependent on Rho-kinase [10,11]. pre-
sumably via generation of contractile prostaglandins [11].
Thusfar, no reports have been published on a differential
role for Rho-kinase in airway responsiveneness to contrac-
tile agonists in vivo.
Recently, Rho-kinase has emerged to be a potential target
in airways diseases, including allergic asthma [12]. Ex vivo,
it has been demonstrated that Rho/Rho-kinase-mediated
Ca2+-sensitization is enhanced in acetylcholine-induced
contraction of bronchial smooth muscle obtained from
repeatedly allergen-challenged rats [13]. Moreover, we
have recently demonstrated that active allergic sensitiza-
tion (without subsequent allergen exposure) increased
contractile potency of guinea pig tracheal smooth muscle
preparations towards histamine and PGF2α  in a Rho-
kinase dependent fashion. Similarly, passive sensitiza-
tion-induced nonspecific ASM hyperresponsiveness and
specific allergen responsiveness in these preparations
were found to be dependent on Rho-kinase as well [14].
Also in vivo, using permanently instrumented, unanaes-
thetized, unrestrained guinea pigs, we found that the con-
tribution of Rho-kinase to airway responsiveness to
histamine was augmented after active allergic sensitiza-
tion [9]. However, the contribution of Rho-kinase to the
development of AHR after the allergen-induced early
(EAR) and late (LAR) asthmatic reaction in this model is
presently unknown.
In the present study, using the same model, we therefore
investigated the involvement of Rho-kinase in the airway
responsiveneness to histamine and PGF2α before and after
the allergen-induced EAR and LAR. We demonstrate that
there is a differential role of Rho-kinase in the agonist-
induced airway obstructions and that inhalation of the
specific Rho-kinase inhibitorY-27632 results in a strong
bronchoprotection to both agonists Moreover, the results
indicate that increased Rho-kinase activity contributes to
allergen-induced AHR to histamine and PGF2α after both
the EAR and the LAR, which is effectively reversed by Y-
27632 inhalation.
Methods
Animals
Outbred specified pathogen-free male Dunkin Hartley
guinea pigs (Harlan, Heathfield, U.K.), weighing 500–700
g, were used in this study. The animals were actively IgE-
sensitized to ovalbumin (OA) as described previously
[15]. In short, 0.5 ml of an allergen solution containing
100  μg/ml OA and 100 mg/ml Al(OH)3 in saline was
injected intraperitoneally, while another 0.5 ml was
divided over seven intracutaneous injection sites in the
proximity of lymph nodes in the paws, lumbar regions
and the neck. The animals were operated 2 weeks after
sensitization and used experimentally in weeks 4 to 8 after
sensitization. The animals were group-housed in individ-
ual cages in climate controlled animal quarters and given
water and food ad libitum, while a 12-h on/12-h off light
cycle was maintained. All protocols described in this study
were approved by the University of Groningen Commit-
tee for Animal Experimentation.
Measurement of airway function
Airway function was assessed in conscious, permanently
instrumented, unrestrained guinea pigs, by on-line meas-
urement of pleural pressure (Ppl) as described previously
[16]. In short, a small saline-filled balloon-catheter was
surgically implanted inside the thoracic cavity. The free
end of the catheter was driven subcutaneously to the neck
of the animal, where it was exposed and attached perma-
nently. Via an external saline-filled canula the pleural bal-
loon was connected to a pressure transducer (Ohmeda
DTX, SpectraMed, Bilthoven, the Netherlands) and an on-
line computer system, enabling continuous measurement
of Ppl changes (in cm H2O). We have previously foundRespiratory Research 2006, 7:121 http://respiratory-research.com/content/7/1/121
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that changes in Ppl are linearly correlated with changes in
airway resistance and hence can be used as a sensitive
index for bronchoconstriction [16].
Provocation procedures
Provocations with OA, histamine and PGF2α, as well as
administration of Y-27632 were performed by inhalation
of aerosolized solutions. Aerosols were produced by a
DeVilbiss nebulizer (type 646; DeVilbiss, Somerset, PA,
USA), driven by an airflow of 8 l/min and resulting in an
output of 0.33 ml/min. Provocations were carried out in a
perspex cage (internal volume of 9 l) in which the guinea
pigs could move freely [16]. Before the start of the experi-
ment, the animals were habituated to the experimental
conditions on two sequential days at least one week after
surgery, when preoperative weight had been restored. On
the first day, the animals were placed in the provocation
cage unconnected to the pressure transducer. After an
adaptation period of at least 30 min, three consecutive
provocations with saline were performed, each exposure
lasting 3 min and separated by a 7-min interval. The next
day, this procedure was repeated with the animals con-
nected to the measurement system.
On the experimental days, following the habituation pro-
cedure, OA, histamine and PGF2α provocations were per-
formed as described below. All provocations were
preceded by an adaptation period of at least 30 min, fol-
lowed by two consecutive control provocations with
saline as described above. Baseline Ppl was calculated by
averaging the Ppl of the last 20 min of the adaptation
period.
To assess the airway reactivity to histamine, provocations
were performed with an initial 25 μg/ml histamine solu-
tion in saline, followed by increasing dosage steps of 25
μg/ml. Histamine provocations lasted 3 min, separated by
7 min intervals. Animals were challenged until Ppl was
increased by more than 100 % above baseline for at least
3 consecutive minutes. Ppl  returned to baseline value
within 15 min after the last provocation. The provocation
concentration causing a 100 % increase of Ppl (PC100-
value) was derived by linear intrapolation of the concen-
tration-Ppl curve and was used as a measure for airway
reactivity toward the agonist. Using the same procedure,
airway reactivity to PGF2α  was determined by using
increasing concentrations of 1.25, 2.5, 5, 10, 15, 20, 37.5,
50, 75, 100 and 125 μg/ml of PGF2α in saline, respectively.
OA-provocations were performed by inhalation of
increasing aerosol concentrations of 0.5 and 1.0 mg/ml
OA in saline for 3 min, separated by 7 min intervals. Aller-
gen inhalations were discontinued when an increase in Ppl
of more than 100 % was observed. Using these condi-
tions, none of the animals developed anaphylactic shock
after allergen provocation.
Provocation protocol
On two different occasions, separated by a one week inter-
val, histamine or PGF2α PC100-values were assessed 24 h
before OA-challenge, and at 5 h and 23 h after the OA-
challenge, i.e. after the early (EAR) and late (LAR) asth-
matic reaction, respectively. Thirty minutes after each his-
tamine or PGF2α inhalation, saline or Y-27632 (5 mM)
was nebulized during 3 min, followed by reassessment of
the histamine or PGF2α PC100-values 30 min later. Saline
and Y-27632 inhalations were alternated using a random
crossover design.
Data analysis
All data represent means ± s.e. mean from n  separate
experiments. Statistical significance of differences was
evaluated using a repeated measures one way analysis of
variance (ANOVA) followed by a Holm-Sidak post-test,
and significance was accepted when P < 0.05.
Chemicals
Ovalbumin (grade III) and histamine dihydrochloride
were obtained from Sigma Chemical Co. (St. Louis, MO,
U.S.A.). PGF2α was obtained from Pharmacia and Upjohn
(Puurs, Belgium) and (+)-(R)-trans-4-(1-aminoethyl)-N-
(4-pyridyl) cyclohexane carboxamide (Y-27632) was
obtained from Tocris Cookson Ltd. (Bristol, U.K.). All
other chemicals were of analytical grade.
Results
In contrast to saline (Fig. 1A), Y-27632 significantly
decreased the basal responsiveness toward histamine
before OA-challenge, as indicated by an increased PC100
(Fig. 1B). After the EAR, AHR had developed (Fig. 1A and
1B), which was reversed by Y-27632 to the level of basal
responsiveness in the absence of the Rho-kinase inhibitor
(Fig. 1B). Interestingly, the AHR after the LAR was even
fully reversed to the basal responsiveness in the presence
of Y-27632 (Fig. 1B). Saline inhalations did not affect his-
tamine PC100-values after the EAR and LAR (Fig. 1A).
As shown in figure 2B, basal responsiveness to PGF2α was
also significantly inhibited by Y-27632 inhalation to a
considerable extent. The AHR after the EAR was strongly
reversed by Y-27632 inhalation to a hyporesponsive level
as compared to basal airway responsiveness in the
absence of the Rho-kinase inhibitor (P < 0.05). As for his-
tamine, Y-27632 inhalation fully reversed the AHR to
PGF2α after the LAR to the basal responsiveness as meas-
ured in the presence of Y-27632 (Fig. 2B). As with hista-
mine, saline inhalations did not affect PC100 values for
PGF2α (Fig. 2A).
As compared to basal conditions (1.7 ± 0.1-fold decrease
of airway responsiveness), the effectiveness of Y-27632 to
reduce the airway responsiveness to histamine after theRespiratory Research 2006, 7:121 http://respiratory-research.com/content/7/1/121
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EAR (3.3 ± 0.4-fold) and after the LAR (2.3 ± 0.1-fold) was
significantly increased (P < 0.05 both; Fig. 3A). Also for
PGF2α, Y-27632 inhalation was much more effective in
reducing the airway responsiveness after the EAR (7.3 ±
1.1-fold, P < 0.05) and the LAR (5.6 ± 0.7-fold, P < 0.05)
as compared to pre-challenge conditions (3.8 ± 0.5-fold
decrease, Fig. 3B). Interestingly, under all conditions Y-
27632 was significantly more effective in reducing airway
responsiveness to PGF2α as compared to histamine, indi-
cating that there is a receptor-dependent role for Rho-
kinase in airway responsiveness in vivo. In addition, we
found that there is a clear tendency (P = 0.08) for a more
pronounced degree of AHR after the EAR for PGF2α (5.8 ±
1.1-fold increase in airway reactivity) than for histamine
(3.3 ± 0.4-fold increase in airway reactivity). No difference
was observed in the degree of AHR after the LAR for both
agonists (1.7 ± 0.2 and 1.6 ± 0.2 for PGF2α and histamine,
respectively).
Discussion
In the present study, we demonstrated that inhalation of
the Rho-kinase inhibitor Y-27632 causes a considerable
bronchoprotection against histamine and PGF2α under
basal conditions. Moreover, we showed for the first time
that in conscious, freely moving, actively OA-sensitized
guinea pigs, inhalation of the Rho-kinase inhibitor Y-
27632 reverses the AHR to both agonists after the aller-
gen-induced EAR and LAR. The results strongly indicate
that an increased Rho-kinase activity is involved in the
development of the allergen challenge-induced AHR, as
demonstrated by an enhanced effectiveness of Y-27632 to
inhibit the increased airway responsiveness to histamine
and PGF2α, both after the EAR and the LAR.
Further investigations are warranted to reveal the exact
mechanisms underlying the increased contribution of
Rho-kinase to airway responsiveness after the EAR and
LAR. Evidence exists that allergic sensitization by itself is
already a key process in augmenting the role of Rho-
kinase in contractile airway responsiveness. Thus, we pre-
viously found that active allergic sensitization by itself,
without subsequent allergen exposure, is sufficient to
induce an enhanced role of Rho-kinase in guinea pig air-
way smooth muscle contraction ex vivo and airway
responsiveness  in vivo [9]. Also in passively sensitized
guinea pig tracheal preparations, we recently found that
the nonspecific hyperresponsiveness in response to hista-
mine and methacholine was fully normalized by Rho-
kinase inhibition [14]. The enhanced contribution of
Rho-kinase to airway responsiveness could involve
increased expression of RhoA, as protein levels of this
upstream activator of Rho-kinase have been reported ele-
Effects of saline (A) and Y-27632 (5 mM nebulizer concentration; B) inhalations on airway responsiveness toward histamine  after the allergen-induced EAR and LAR Figure 1
Effects of saline (A) and Y-27632 (5 mM nebulizer concentration; B) inhalations on airway responsiveness toward histamine 
after the allergen-induced EAR and LAR. Data represent means ± s.e.mean of 5 animals. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to basal; #P < 0.05, ## P < 0.01 compared to control.Respiratory Research 2006, 7:121 http://respiratory-research.com/content/7/1/121
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vated both after allergic sensitization in guinea pigs [9]
and after repeated allergen challenge in rats [13] and mice
[17]. Inflammatory cells – activated during the allergic
reaction – release mediators, including prostaglandins,
leukotrienes and growth factors [18,19], which have been
reported to be dependent on Rho-kinase for their contrac-
tile effects [10,11]. It can be envisaged that there is syner-
gism in Rho-kinase activation between such mediators
and the inhaled agonists, which results in a higher efficacy
of Rho-kinase inhibition. In addition, Rho-kinase inhibi-
tion might have effects on airway inflammation itself, as
has been suggested in a murine model of acute allergic air-
way inflammation. In anaesthetized mice, it was found
that when Y-27632 was given intranasally prior to allergen
challenge, pulmonary eosinophilia was reduced, as
shown by a decreased number of eosinophils in the bron-
choalveolar lavage (BAL) fluid [20]. In the same study, it
was also demonstrated that intranasally administered Y-
27632, which was given before every allergen challenge,
reduced the repeated allergen-induced increased respon-
siveness to intravenously applied methacholine, which
might be correlated to effects on airways inflammation
[20]. Also, it has been demonstrated in vitro that Y-27632
decreased the release of the Th2 cytokines IL-4 and IL-5
[21].
It has been previously reported that a differential contri-
bution of Rho-kinase to histamine- and PGF2α-induced
ASM contraction exists in vitro [9]. Fully in line with those
findings, we found that such a differential role of Rho-
kinase also exists in vivo. Thus, under all conditions inha-
lation of Y-27632 was significantly more effective in
reducing airway responsiveness to PGF2α as compared to
histamine. Moreover, there was a strong tendency to a
more pronounced AHR after the EAR in response to PGF2α
as compared to histamine. Together with the higher effi-
cacy by which Y-27632 inhalation reduces airway respon-
siveness to PGF2α as compared to histamine, this might
suggest that the severity of AHR to a certain agonist is asso-
ciated with the extent to which the agonist is dependent
on Rho-kinase for its contractile effect.
Conclusion
Inhalation of the Rho-kinase inhibitor Y-27632 causes a
considerable bronchoprotection to histamine and PGF2α.
Moreover, a differential involvement of Rho-kinase in the
contractile agonist-induced airway obstructions exists in
vivo. Increased Rho-kinase activity contributes to the aller-
gen-induced AHR to histamine and PGF2α after both the
EAR and the LAR, which is effectively reversed by inhala-
tion of Y-27632. Therefore, Rho-kinase can be considered
as a potential pharmacotherapeutical target in allergic
asthma.
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Effects of saline (A) and Y-27632 (5 mM nebulizer concentration; B) inhalations on airway responsiveness toward PGF2α after  the allergen-induced EAR and LAR Figure 2
Effects of saline (A) and Y-27632 (5 mM nebulizer concentration; B) inhalations on airway responsiveness toward PGF2α after 
the allergen-induced EAR and LAR. Data represent means ± s.e.mean of 7 animals. *P < 0.05, **P < 0.01, ***P < 0.001 com-
pared to basal; ##P < 0.01, ### P < 0.001 compared to control.Respiratory Research 2006, 7:121 http://respiratory-research.com/content/7/1/121
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